Exogenous leptin enhances markers of airway fibrosis in a mouse model of chronic allergic airways disease

Mark D. Ihrie1, Victoria L. McQuade1, Jack T. Womble1, Akhil Hegde2, Matthew S. McCravy1, Cyrus Victor G. Lacuesta2, Robert M. Tighe1, Loretta G. Que1, Julia K. L. Walker1,2 and Jennifer L. Ingram1,3*

Abstract

Background: Asthma patients with comorbid obesity exhibit increased disease severity, in part, due to airway remodeling, which is also observed in mouse models of asthma and obesity. A mediator of remodeling that is increased in obesity is leptin. We hypothesized that in a mouse model of allergic airways disease, mice receiving exogenous leptin would display increased airway inflammation and fibrosis.

Methods: Five-week-old male and female C57BL/6J mice were challenged with intranasal house dust mite (HDM) allergen or saline 5 days per week for 6 weeks (n = 6–9 per sex, per group). Following each HDM exposure, mice received subcutaneous recombinant human leptin or saline. At 48 h after the final HDM challenge, lung mechanics were evaluated and the mice were sacrificed. Bronchoalveolar lavage was performed and differential cell counts were determined. Lung tissue was stained with Masson’s trichrome, periodic acid-Schiff, and hematoxylin and eosin stains. Mouse lung fibroblasts were cultured, and whole lung mRNA was isolated.

Results: Leptin did not affect mouse body weight, but HDM+leptin increased baseline blood glucose. In mixed-sex groups, leptin increased mouse lung fibroblast invasiveness and increased lung Col1α1 mRNA expression. Total lung resistance and tissue damping were increased with HDM+leptin treatment, but not leptin or HDM alone. Female mice exhibited enhanced airway responsiveness to methacholine with HDM+leptin treatment, while leptin alone decreased total respiratory system resistance in male mice.

Conclusions: In HDM-induced allergic airways disease, administration of exogenous leptin to mice enhanced lung resistance and increased markers of fibrosis, with differing effects between males and females.

Keywords: Leptin, Asthma, Airway remodeling, Sex differences

Background

In the past two decades, the prevalence of asthma and obesity has increased, making them crucial public health-care issues. In 2017, the prevalence of asthma and obesity among adults in the United States was 7.9% and 42.4%, respectively [1, 2]. Furthermore, nearly 40% of patients in the United States with asthma exhibit comorbid obesity [3]. These patients display decreased sensitivity to inhaled corticosteroid therapy and glucocorticoid resistance, which contribute to increased asthma severity, poor asthma control, and disproportionately high use of healthcare resources [4–6]. Therefore, it is critical that we understand the mechanisms underlying the relationship between asthma and obesity.
In adult asthma with comorbid obesity, two distinct endotypes may be distinguished based on age of asthma onset: early-onset asthma, which is associated with the development of asthma early in life (<12 years of age), the treatment of which is complicated by obesity in adulthood; and late-onset asthma, which is associated with the development of asthma in adolescence or adulthood and may occur as a consequence of obesity [7]. Early-onset asthma is generally characterized by atopy, airway hyperresponsiveness, overproduction of airway mucus, type 2-cytokine-driven eosinophilic inflammation, and airway fibrosis [8]. The pathogenesis of this allergic asthma begins with immunological sensitization to environmental allergens, which derive from mold, pollen, or invertebrates such as house dust mites [9]. Briefly, antigens from these allergens are taken up by antigen-presenting cells in the lung, which activate naïve helper T cells, creating a T helper 2 (Th2) immune response [8]. This Th2 environment is characterized by the type 2 cytokines interleukins (IL)-4, -5, and -13 and antigen-specific immunoglobulin E (IgE), all of which perpetuate inflammation in the airway [8]. Eosinophils are recruited to the lung by IL-5 and eotaxin (CCL11) released by Th2 and mast cells, where they mediate the production of histamines and leukotrienes [8]. Chronic inflammation in asthma leads to airway remodeling and fibrosis, characterized by increased subepithelial collagen deposition [8]. Transforming growth factor (TGF)-β1 is a major mediator of fibrogenesis and promotes fibroblast proliferation and collagen synthesis [8]. Evidence from the literature indicates that the airway fibrosis component of asthma may be an important contributor to the relationship between asthma and obesity; in early-onset asthma, obesity and insulin resistance are associated with airway remodeling [10–13].

One way in which obesity may influence airway fibrosis in asthma is through the adipokine, leptin. Leptin, long known for its role in energy balance, is produced mainly by adipose tissue and acts to suppress hunger, increasing homeostatic energy consumption [14]. Circulating leptin levels are increased in patients with obesity, and these individuals may experience leptin resistance; that is, these increased leptin levels no longer promote satiety [14]. The precise mechanism through which leptin resistance occurs in these patients has yet to be determined, but may involve impaired leptin transport across the blood–brain barrier and decreased hypothalamic sensitivity to leptin [14, 15]. Mice that are leptin-deficient exhibit extreme weight gain [16]. Additionally, leptin-deficient mice exhibit impaired extracellular matrix remodeling in lung and heart, indicating a potential role for leptin in fibrotic processes [17, 18]. Furthermore, exogenous leptin administration in these mice promotes collagen production [17, 18]. Also, leptin signaling is necessary for bleomycin-induced lung fibrosis through a mechanism of peroxisome proliferator-activated receptor gamma (PPARγ) inhibition, which results in enhanced TGF-β1 signaling [19]. While these studies point to leptin’s pro-fibrotic role, the impact of increased serum leptin levels in obesity on asthma pathobiology is less well understood.

In the present study, we sought to determine how exogenous leptin administration to lean, normal chow-fed mice would impact asthmatic endpoints in chronic house dust mite (HDM)-induced allergic airway disease. We hypothesized that mice receiving exogenous leptin would display increased airway inflammation and fibrosis. Our findings indicate that increased leptin levels in obesity may contribute to airway fibrosis and hyperresponsiveness and that the impact of leptin on asthma outcomes may depend on sex.

Methods

Animals

Five-week-old male and female C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME). Animal care and experimental protocols were approved by the Duke University Institutional Animal Care and Use Committee and carried out in accordance with the American Association for the Accreditation of Laboratory Animal Care guidelines. All mice were housed in pathogen-free facilities at Duke University. Mice were weighed and tested for glucose tolerance at weeks 0 and 6 of the protocol.

Diet and treatments

Mice were fed normal chow (LabDiet 5053) ad libitum and received intranasal phosphate-buffered saline (PBS) or HDM allergen (Greer Laboratories (Lenoir, NC, USA), XPB70D3A2.5, lot #360924, 50 µg protein in 40 µl PBS) 5 days per week for 6 weeks under light isoflurane anesthesia. Immediately following each HDM dose, mice received subcutaneous injections of recombinant human leptin [20] (Sigma-Aldrich (St. Louis, MO) L4146) (1 mg/kg) or PBS (see Additional file 1: Fig. S1). There were 6–9 mice per sex, per treatment group (4 treatment groups), for a total of 60 mice.

Oral glucose tolerance test

Mice were fasted for 5 h prior to the glucose tolerance test. Tail blood was treated with 5% lidocaine, and 200 µl of 10% glucose solution was administered by oral gavage. The mice were restrained, and blood was collected from the tail vein. Blood was collected prior to gavage and at 10-, 30-, and 90-min post-gavage. Glucose levels were

---

**Figure 1:**

**Figure 1:**

In the present study, we sought to determine how exogenous leptin administration to lean, normal chow-fed mice would impact asthmatic endpoints in chronic house dust mite (HDM)-induced allergic airway disease. We hypothesized that mice receiving exogenous leptin would display increased airway inflammation and fibrosis. Our findings indicate that increased leptin levels in obesity may contribute to airway fibrosis and hyperresponsiveness and that the impact of leptin on asthma outcomes may depend on sex.

**Methods**

**Animals**

Five-week-old male and female C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME). Animal care and experimental protocols were approved by the Duke University Institutional Animal Care and Use Committee and carried out in accordance with the American Association for the Accreditation of Laboratory Animal Care guidelines. All mice were housed in pathogen-free facilities at Duke University. Mice were weighed and tested for glucose tolerance at weeks 0 and 6 of the protocol.

**Diet and treatments**

Mice were fed normal chow (LabDiet 5053) ad libitum and received intranasal phosphate-buffered saline (PBS) or HDM allergen (Greer Laboratories (Lenoir, NC, USA), XPB70D3A2.5, lot #360924, 50 µg protein in 40 µl PBS) 5 days per week for 6 weeks under light isoflurane anesthesia. Immediately following each HDM dose, mice received subcutaneous injections of recombinant human leptin [20] (Sigma-Aldrich (St. Louis, MO) L4146) (1 mg/kg) or PBS (see Additional file 1: Fig. S1). There were 6–9 mice per sex, per treatment group (4 treatment groups), for a total of 60 mice.

**Oral glucose tolerance test**

Mice were fasted for 5 h prior to the glucose tolerance test. Tail blood was treated with 5% lidocaine, and 200 µl of 10% glucose solution was administered by oral gavage. The mice were restrained, and blood was collected from the tail vein. Blood was collected prior to gavage and at 10-, 30-, and 90-min post-gavage. Glucose levels were
determined by an Accu-Chek Performa (Roche, Basel, Switzerland) blood glucose meter.

**Lung physiology measurement**

Airway responsiveness to methacholine was measured 48 h after the final HDM exposure using a computer-controlled small animal ventilator (FlexiVent, Scireq (Montreal, Canada)) as described [21]. At the conclusion of airway physiology measurements, mice were euthanized by pentobarbital overdose and tissues were immediately harvested.

**Plasma biomarkers**

Immediately following airway physiology measurements and euthanasia, blood was collected by cardiac puncture and placed in a BD Microtainer lithium heparin blood tube with protease inhibitor (aprotinin and diprotin A). The blood was centrifuged at 10,000 RPM to isolate serum. Serum IgE levels were measured using Invitrogen ELISA (# 88-50460-22) (Waltham, MA) according to manufacturer protocol (plasma diluted 50 \( \times \)). Mouse and human leptin levels in serum were measured by DuoSet ELISA (R&D Systems, Minneapolis, MN) according to manufacturer protocol.

**Bronchoalveolar lavage (BAL)**

After blood collection, lungs were lavaged with 1 ml PBS three times. BAL cells were separated by centrifugation and total cells were counted with a Scepter Handheld Automated Cell Counter (MilliporeSigma) (Burlington, MA, USA). Cells were attached to slides using a Cyto spin 3 Cytocentrifuge (ThermoFisher) (Waltham, MA, USA) and fixed and stained with Easy III (Azer Scientific) (Morgantown, PA, USA). Differential cell counts were obtained by counting 200 total cells under \( \times 200 \) magnification. Mouse DuoSet ELISAs for leptin, IL-5, CCL11, and TGF-β1 were obtained from R&D Systems (Minneapolis, MN, USA) and carried out according to manufacturer protocol to measure these proteins in BAL fluid.

**Lung histology**

After removal of the right lung, the left lung was inflated to 25 cmH₂O and fixed in 4% paraformaldehyde. Following fixation, the lung was embedded in paraffin, sectioned (two sections per slide), and stained with hematoxylin and eosin (H&E), Masson's trichrome, and periodic acid-Schiff (PAS) stains.

**H&E scoring**

Blinded, tiered, semi-quantitative scoring was performed on H&E-stained lung sections. Ten airways per slide were randomly selected and given a score from 0 to 4 (0 being a normal airway, and 4 being the most inflamed airway observed) for both percentage of airway circumference surrounded by inflammatory infiltrate, and depth of inflammatory infiltrate. These two scores were averaged together, and the scores from all 10 airways were averaged to derive the average inflammatory score per mouse.

**PAS scoring**

Blinded, tiered, semi-quantitative scoring was performed on PAS-stained lung sections. Ten airways per slide were randomly selected and given a score from 0 to 4 for the percentage of airway circumference exhibiting positive PAS staining. The scores from the ten airways were averaged to derive the average PAS score per mouse.

**Trichrome analysis**

Semi-quantitative morphometric analysis was performed on trichrome-stained lung sections. Ten circular to oval-shaped airways were randomly chosen per slide and images taken at \( \times 200 \) magnification. Using ImageJ, the free-draw tool was used to trace around the circumference of the collagen layer surrounding the airway, and around the circumference of the airway lumen. These measurements give the total area and the lumen area; the lumen area is subtracted from the total area to yield the airway area. The blue trichrome stain was then isolated by using the color threshold setting to set the hue to the blue spectrum. This area of positive blue staining was measured, and the percent positive trichrome stain was derived by dividing positive stain area by the airway area and multiplying by 100.

**RNA isolation from mouse lung**

At harvest, the right middle lung lobe was placed directly into 1 ml of TRI Reagent. The lobe was then homogenized using a Biospec Tissue-Tearor power homogenizer. 200 μl chloroform was added, tubes were shaken for 15 s, then incubated at room temperature for 3 min, followed by centrifugation at 12,500 RPM for 15 min at 4 °C. The upper aqueous phase was removed and placed in a new tube. 500 μl of 100% isopropanol was added to the aqueous phase, then incubated at room temperature for 10 min at 4 °C. Next, the supernatant was removed, leaving the RNA pellet, which was washed twice with 1 ml of 75% ethanol. Pellets were air-dried for 10 min, then were resuspended in 20 μl of RNase-free water.

**mRNA quantification**

RNA concentration was measured on a NanoDrop ND-1000 (ThermoFisher) and cDNA was prepared using the Applied Biosystems High-Capacity Reverse Transcription Kit. Quantitative real-time polymerase chain reaction (qRT-PCR) was then performed using
Applied Biosystems (Waltham, MA, USA) TaqMan Gene Expression Master Mix and TaqMan primers (Gapdh Mm99999915_g1, Colla1 Mm00801666_g1, Muc5ac Mm01276718_g1, Muc5b Mm00466391_m1, Eln Mm00514670_m1). Fold change was calculated with the delta Ct method using the PBS+saline average as the control treatment, and Gapdh as the endogenous control.

Ex vivo invasion assay
Primary mouse lung fibroblast cultures were established from lung tissue digests from experimental mice. The right lower and accessory lung lobes were homogenized in Dulbecco’s Modified Eagle Medium (DMEM) containing 5% fetal bovine serum, 10 mM HEPES, 10% collagenase, and 1.4% DNase 1 using a GentleMACS dissociator (Miltenyi Biotec) (Bergisch Gladbach, Germany). The cell suspension was filtered through a 70-μm strainer, resuspended in DMEM supplemented with 10% fetal bovine serum, and plated into 75 cm² cell culture flasks for lung fibroblast cultures and grown at 5% CO₂ and 37 °C. Fresh media was added every 2–3 days until the cells reached >80% confluence. Fibroblasts from all groups of experimental mice were cultured and passaged under identical conditions. Invasion/migration assays were performed as described [22]. Briefly, cells at 80% confluence were resuspended in serum-free media (SFM) and seeded onto Matrigel and non-Matrigel control (BD Biosciences, San Jose, CA, USA) 24-well transwell plates (8.0 μm pore size) at 100,000 cells per insert. The cells were incubated in the presence of SFM in the apical and basal compartments of the transwell for 48 h. Following the incubation, the lower side of the inserts was stained using a Diff-Quik kit. The stained invading or migrating cells were counted under ×10 magnification.

Statistical analysis
Statistical analyses were performed in GraphPad Prism 9. The distribution of the data was examined visually, outliers were tested with the Robust Regression and Outlier Removal method [23] and were removed where appropriate. Data were evaluated for normality via the Anderson–Darling test. Parametric or non-parametric tests were employed accordingly (one, two, or three-way ANOVA or Kruskal–Wallis), with appropriate post-test (specific tests are noted in figure legends). Significance is denoted by p < 0.05, and all data are presented as the mean ± SEM.

Results
Exogenous leptin administration in HDM exposed mice increases baseline blood glucose levels but does not affect weight gain. Overall, serum leptin levels did not significantly differ between exposure conditions (see Additional file 1: Fig. S2A); yet baseline levels of circulating leptin in control mice (intranasal PBS with subcutaneous saline) were significantly elevated in male mice compared to female mice (see Additional file 1: Fig. S2B). Mice were weighed weekly throughout the course of the 6-week exposure to leptin and HDM, and no significant changes in cumulative weight gain were seen between groups. However, the leptin-treated groups tended to have reduced weight gain compared to saline-treated groups (Fig. 1A). Glucose tolerance was assessed at week 0 prior to beginning treatment and at week 6. While no differences in glucose response were seen between conditions at week 0 or week 6 (Fig. 1B, C), the change in baseline blood glucose levels over the course of the protocol was significantly higher in HDM+leptin exposed mice compared with PBS+saline (Fig. 1D). Area under the curve analysis was performed on glucose tolerance data, however, it indicated no significant changes between conditions (see Additional file 1: Fig. S3).

Markers of airway fibrosis are increased by leptin treatment. Representative photomicrographs of Masson’s trichrome-stained lung sections indicate typically observed increased airway inflammation and peribronchiolar collagen deposition in HDM-exposed groups compared to PBS-exposed groups (Fig. 2A). Quantification of peribronchiolar trichrome staining revealed a significant increase in collagen deposition with HDM exposure compared with PBS control (Fig. 2B). Lung fibroblast invasiveness was evaluated ex vivo via invasion/migration assay, which showed that leptin treatment significantly increased baseline percent invasion of mouse lung fibroblasts relative to saline treated mice (Fig. 2C). There were no effects of HDM exposure on fibroblast invasiveness (Additional file 1: Fig. S4D) Additionally, whole lung type I collagen (Colla1) mRNA levels displayed a similar response, with leptin significantly increasing levels over saline in lung fibroblasts isolated from HDM-exposed mice (Fig. 2D). Levels of elastin (Eln) mRNA were also measured but no significant differences between conditions were observed (see Additional file 1: Fig. S4C). Total TGF-β1 protein levels in BAL fluid indicated a significant HDM effect, however, no change was seen with leptin treatment (Fig. 2E).

HDM increases airway inflammation and BAL eosinophil and lymphocyte numbers, while leptin decreases BAL lymphocytes. Scoring of peribronchiolar inflammation revealed that HDM-challenged mice exhibited significantly enhanced airway inflammation independent of leptin treatment (Fig. 3B). Total counts of BAL fluid eosinophils were significantly increased in HDM-challenged mice compared to saline-treated mice, independent of leptin treatment (Fig. 3C). In contrast, leptin treatment significantly reduced HDM-induced BAL lymphocyte numbers compared to HDM/saline-treated mice.
**Fig. 1** Weight gain and glucose tolerance. A Change in mouse weight from week 0 to week 6, n = 12–18 mice per group. B, C Glucose tolerance curves at B week 0 and C week 6. D Change in baseline blood glucose level from week 0 to week 6, n = 12–18 mice per group. *p < 0.05 HDM+saline vs. HDM+leptin by two-way ANOVA with Tukey’s post hoc test.

**Fig. 2** Changes in profibrotic endpoints. A Representative images of Masson’s trichrome-stained mouse lung sections taken at ×100 magnification, scale bar = 250 μm. Blue staining around the airways indicates positive trichrome staining. B Quantification of mean Masson’s trichrome staining, n = 12–18 mice per group, 10 airways per mouse. C Mean percent invasion in control treated fibroblasts (number of invading cells divided by number of migrating cells × 100) lung fibroblasts determined by Matrigel invasion assay, n = 10–12 mice per group, cultures performed in duplicate. D Col1a1 mRNA expression in whole lung, n = 5–8 mice per group. E Total TGF-β1 protein levels in BAL n = 12–18 mice per group; *p < 0.05, **p < 0.01, ****p < 0.0001 vs. corresponding PBS treatment, †p < 0.01 vs. saline by two-way ANOVA with Šidák correction.
Fig. 2 (See legend on previous page.)
**Fig. 3** Changes in peribronchial inflammation and BAL cellularity. 

A. Representative images of H&E-stained mouse lung sections taken at ×100 magnification, scale bar = 250 μm. 

B. Mean peribronchial inflammation score of H&E-stained lung sections, n = 12–18 mice per group, 9 airways per mouse. 

C–F. Relative numbers of C. eosinophils, D. neutrophils, E. lymphocytes, and F. macrophages in BAL were evaluated, n = 8–12 mice per group. 

G. IL-5 and H. CCL11 levels measured in BAL fluid, n = 12–18 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. corresponding PBS treatment; #p < 0.05, ####p < 0.0001 vs. HDM + saline by two-way ANOVA with Šidák correction.
(Fig. 3E). Changes in eosinophil and lymphocyte numbers were reflected as decreases in macrophage numbers, but numbers of airway neutrophils were not significantly different between conditions (Fig. 3D, F). HDM challenge induced significantly increased IL-5 and CCL11 levels in BAL fluid compared to saline-treated mice; further, leptin treatment significantly reduced IL-5, but not CCL11, in HDM-exposed mice compared to HDM alone (Fig. 3G, H).

HDM exposure with exogenous leptin administration increases airway mucus production, Muc5ac mRNA expression, and serum IgE. Scoring of peribronchiolar mucin in PAS-stained lung sections demonstrated that HDM exposure significantly enhanced airway mucus production alone and with leptin administration, while leptin alone had no effect. (Fig. 4B). Muc5ac mRNA levels in whole lung were significantly increased in the HDM+leptin group, but not HDM alone (Fig. 4C), while no significant differences between groups were seen in Muc5ac protein levels or Muc5b mRNA expression (see Additional file 1: Fig. S4A, B). Serum IgE levels were significantly increased by HDM in both saline and leptin-administered mice; while leptin alone did not significantly affect IgE levels, there was an upward trend with leptin administration (Fig. 4D).

Total lung resistance and tissue damping are increased by HDM exposure with exogenous leptin administration. Lung mechanics were assessed at 6 weeks of chronic HDM exposure and leptin administration. In mixed-sex groups, total respiratory resistance (Rtot) was significantly increased in the HDM+leptin group compared with the leptin alone group, but not compared with the HDM alone group (Fig. 5A). Percent change in total respiratory resistance was also significantly increased by HDM+leptin compared with leptin alone, however, this parameter was also significantly decreased by treatment with leptin alone compared with saline control (Fig. 5B). Similarly, tissue damping (G) was significantly increased by HDM+leptin compared with leptin alone (Fig. 5C, D). Newtonian resistance (Rn), elastance (E), and tissue elastance (H) were also measured; however, no significant changes between groups were seen (see Additional file 1: Fig. S5).

Sex-dependent differences are present in HDM-induced airway hyperresponsiveness, mucus production, and TGF-β1 levels with evidence of leptin-specific effects. While HDM exposure alone did not increase Rtot in male mice, it significantly increased Rtot in females, independent of leptin treatment (Fig. 6B). Furthermore, leptin treatment had no effects on Rtot in female mice (Fig. 6B). Conversely, leptin treatment in male mice significantly decreased total respiratory resistance (Rtot) in the absence of HDM, but when combined with HDM exposure an increase in Rtot was seen (Fig. 6A). While HDM challenge resulted in significantly increased peribronchiolar PAS staining regardless of leptin treatment in mixed-sex groups (Fig. 4A), only male mice, not female, exhibited significantly increased PAS staining with HDM exposure. (Fig. 6C). Conversely, while both male and female mice showed increased total TGF-β1 protein levels in BAL with HDM+leptin, female mice, but not male, had significantly higher TGF-β1 levels in response to HDM alone (Fig. 6D).

**Discussion**

In this study, we investigated the effects of leptin in a mouse model of chronic, allergic airways disease. While several studies have previously investigated the role of leptin in lung injury and disease, this study is the first to examine the effects of leptin on chronic, HDM-induced allergic airway disease. Importantly, this study demonstrates the impact of leptin on airway physiology, fibrosis, and inflammation, in addition to examining sex-dependent differences. The present study’s key findings were that while chronic HDM exposure causes airway inflammation, in mixed-sex groups, significant increases in airway resistance only occurred with the addition of exogenous leptin, and leptin increased markers of airway fibrosis and remodeling. Therefore, this study provides new insight into how leptin may directly affect lung inflammation and fibrosis in asthma.

A recent study by Kurokawa et al. examined the effect of exogenous leptin administration on IL-33-induced lung inflammation in both wildtype and leptin deficient mice [24]. While this study differs from the present study in several ways (it utilizes a different, more short term asthma model, only female mice, and murine exogenous leptin), they also measured airway physiology using the FlexiVent system and found that in wildtype mice, exogenous leptin, when combined with IL-33, increased Rrs (equivalent to Rtot), and did not affect Ers, Rn, and H, which is consistent with our findings [24]. G was not affected by exogenous leptin in their study, while in the present study G was increased by HDM+leptin. While increases in Rtot alone indicate increased central and peripheral airway resistance due to airway narrowing and/or closure, the increase in tissue damping (G) seen with HDM+leptin treatment, along with the lack of change in tissue elastance (H), indicates that central airway narrowing, rather than airway closure, may be resulting from leptin treatment. Furthermore, Kurokawa et al. found that serum leptin levels return to baseline 24 h after injection, which explains why we did not see elevated leptin levels in the present study [24]. Another notable similarity between these studies is that exogenous leptin administration did not alter BAL eosinophil levels.
Fig. 4  Changes in airway mucus production and serum IgE.  

A. Representative images of PAS-stained mouse lung sections taken at ×100 magnification, scale bar = 250 μm. Dark purple staining in the airway epithelium indicates positive PAS staining.  

B. Mean peribronchial mucus score of PAS-stained lung sections, n = 12–18 mice per group, 9 airways per mouse.  

C. Changes in whole lung Muc5ac mRNA expression, n = 5–8 mice per group.  

D. Changes in total serum IgE levels as measured by ELISA, n = 10–16 mice per group. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. corresponding PBS treatment by two-way ANOVA with Šídák correction.
induced by the respective asthma models, but exogenous leptin did significantly decrease BAL IL-5 levels [24].

Several additional studies have investigated the role of leptin in lung disease and injury by utilizing exogenous leptin administration. Shore et al. found that leptin did not affect BAL eosinophil numbers, which is consistent with our present study [25]. Conversely, Shore et al. saw no changes in BAL IL-5 levels with leptin treatment, while we found that leptin significantly decreased HDM-induced IL-5 in BAL [25]. Leptin has been shown to play a role in mediating inflammation after cigarette smoke exposure; leptin-deficient mice exhibit increased neutrophil numbers and decreased CD4⁺ and CD8⁺ cells compared with wild-type mice, while exogenous leptin administration restores inflammatory cell profiles [26]. In the chronic asthma model utilized in the present study, leptin did not alter BAL neutrophils, however, leptin did significantly decrease HDM-induced BAL lymphocyte numbers, suggesting an immunomodulatory role. Interestingly, leptin administered intranasally has been shown to attenuate LPS-induced lung injury [27, 28]. Furthermore, leptin can restore impaired host defense following fasting [29]. These studies indicate leptin can augment immune responses, which may, in the context of asthma, be detrimental. However, in our chronic allergen-challenge study, leptin did not affect lung inflammation but rather had specific effects on lung resistance and remodeling endpoints. A study by Jain et al. found that leptin enhances transcription of profibrotic genes downstream of TGF-β1 by human lung fibroblasts in vitro [19]. We similarly saw an increase in Col1a1 expression in mice treated with HDM and leptin, as well as increased lung fibroblast invasion in vitro, indicating a profibrotic fibroblast phenotype. Additionally, though we did not see a leptin effect on PAS staining for airway mucus, we did observe that leptin increased Muc5ac mRNA; previous studies show that leptin can increase IL-13-induced MUC5AC production in human bronchial epithelial cells [30]. Finally, as leptin

![Graphs showing changes in lung mechanics](image-url)
plays a key role in energy homeostasis, it may seem surprising that we did not see changes in mouse weight with exogenous leptin administration; however, it has been reported previously that leptin administration to mice does not significantly alter body weight [20, 24].

Sex differences in human asthma are well known; women have increased asthma prevalence and are more likely to have severe asthma [31]. Additionally, mouse models show that estrogen increases airway inflammation; however, some studies show that female mice
have enhanced inflammation, while others show no change [31]. It is also known that circulating leptin levels are higher in females, and that leptin levels generally correlate with body fat percentage [32, 33]. Evidence also shows that sex hormones may affect the metabolic actions of leptin, with estrogens enhancing the ability of leptin to inhibit eating [34]. Since little is known about how leptin influences asthma, it is also unclear how sex may affect leptin-induced changes. Surprisingly, in our study, despite the combination of HDM+leptin causing increased Rtot in mixed-sex groups, leptin alone significantly decreased Rtot in male mice, while female mice showed no effects from leptin treatment and had a greater response to HDM. One limitation of our study regarding sex-dependent differences is that we did not track the estrus cycle of female mice, so it is possible that this influenced the responses we saw in females. In general, we saw that male mice had enhanced responsiveness to methacholine challenge in both control and HDM-exposed groups compared with female mice. Sex differences in airway responsiveness are variable and dependent on mouse strains. Still, previous literature shows that naive male C57BL/6 mice have enhanced responsiveness compared to females, which is consistent with our study [35, 36]. Furthermore, we saw that only male mice had significantly increased airway mucus production. The lack of significance in female mice may be due to the relatively higher baseline levels of mucus observed in these mice compared with males. Lastly, female mice had significantly higher levels than males, while only male mice exhibited a significant leptin effect. This, taken together with the changes in AHR seen in male mice, suggests that leptin may play a greater role in modulating asthma outcomes in males compared to females.

One limitation of this study is the use of subcutaneous leptin injections instead of direct administration of leptin to the lung through a method such as oropharyngeal aspiration, which might allow for a better understanding of leptin’s direct effects on the lung. It was recently shown that leptin administered intranasally alleviates sleep-disordered breathing, while intraperitoneal leptin injection had no effect [37, 38]. This highlights the importance of the leptin exposure route. Additionally, it is possible that leptin administered subcutaneously could have effects on the central nervous system (CNS), which could then, in turn, impact asthma outcomes. A recent study by Do et al. reports that leptin can act on the CNS to mediate breathing mechanics [39]. Therefore, while subcutaneous leptin administration may mimic increased systemic leptin levels present in obesity, it may be insufficient to elucidate the direct effects of leptin on the lungs. Thus, transgenic overexpression of leptin targeted to the mouse lung may be a more effective way to evaluate leptin’s direct effects on the lung.

**Conclusion**

Our work demonstrates that administration of exogenous leptin to mice can enhance markers of fibrosis and increase lung resistance in a model of allergic airways disease. Furthermore, this study revealed sex differences in response to leptin, indicating that increased leptin levels in obesity may affect males more than females. The lack of significant changes in HDM-induced lung inflammation, together with increased markers of fibrosis, indicates that lung fibrosis may contribute to the observed leptin-induced changes in lung resistance. Further work will be needed to fully elucidate the mechanisms through which leptin affects asthma and fibrosis.

**Abbreviations**

HDM: House dust mite; BAL: Bronchoalveolar lavage; Th2: T helper type 2; IL: Interleukin; IgE: Immunoglobulin E; TGF: Transforming growth factor; PPAR: Peroxisome proliferator activated receptor; PBS: Phosphate buffered saline; H&E: Hematoxylin and eosin; PAS: Periodic acid-Schiff; qRT-PCR: Quantitative reverse transcriptase polymerase chain reaction; DMEM: Dulbecco’s Modified Eagle Medium; SFM: Serum-free media; Rtot: Total lung resistance; G: Tissue damping; Rn: Newtonian resistance; E: Elastance; H: Tissue elastance; CNS: Central nervous system.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12931-022-02048-z.

**Acknowledgements**

Not applicable.

**Author contributions**

MDI: conceptualization, validation, formal analysis, methodology, investigation, writing—original draft. VLM: methodology, investigation, writing—review & editing. JTW: methodology, investigation, writing—review & editing. AH: methodology, investigation, writing—review & editing. MSM: methodology, investigation, writing—review & editing. LGQ: methodology, investigation, writing—review & editing. JKL: methodology, writing—review & editing. JLL: conceptualization, methodology, investigation,
resources, writing—review & editing, funding acquisition. All authors read and approved the final manuscript.

Funding
This work was supported by NIH Grants R01HL130234-04 and R01HL130234-04S1 (JLI).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Animal care and experimental protocols were approved by the Duke University Institutional Animal Care and Use Committee and carried out in accordance with the American Association for the Accreditation of Laboratory Animal Care guidelines.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University, Durham, NC, USA. 2 School of Nursing, Duke University, Durham, NC, USA. 3 Durham, USA.

Received: 14 February 2022   Accepted: 9 May 2022
Published online: 24 May 2022

References

1. Asthma Prevalence. https://www.cdc.gov/asthma/data-visualizations/prevalence.htm.
2. Adult Obesity Facts | Overweight & Obesity | CDC. https://www.cdc.gov/obesity/data/adult.html.
3. AsthmaStats—Asthma and Obesity | CDC. https://www.cdc.gov/asthma/asthma_stats/asthma_obesity.htm.
4. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DYM. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178:682–7.
5. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181:315–23.
6. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005–2009. National Health Statistics Report. 2011, p.1–14.
7. Holguin F, Comhair SAA, Hazen SL, et al. An association between l-arginine asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med. 2013;187:153–9.
8. Holgate ST. Pathogenesis of asthma. In: Kay B, Kaplan AP, Bousquet J, Holt PG, editors. Allergy and allergic diseases. Oxford: Wiley-Blackwell; 2008. p.1608–31.
9. Kim HY, Dekruyff RH, Umetu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010;11:577–84.
10. Bates JHT, Dixon AE. Potential role of the airway wall in the asthma of obesity. J Appl Physiol. 2015;118:36–41.
11. Saraiva SA, Silva AL, Xisto DG, et al. Impact of obesity on airflow and lung parenchyma remodeling in experimental chronic allergic asthma. Respir Physiol Neurobiol. 2011;177:141–8.
12. Sexton P, Black P, Wu L, Sommerville F, Hamed M, Metcalf P, Kolbe J. Fixed airflow obstruction among nonsmokers with asthma: a case-comparison study. J Asthma. 2013;50:606–12.
13. Ge XN, Greenberg Y, Reza Hosseinikhani M, Long EB, Baibaie NS, Rao A, Ha SG, Rao SP, Bernlohr DA, Srinaramao P. High-fat diet promotes lung fibrosis and attenuates airway eosinophilia after exposure to cockroach allergen in mice. Exp Lung Res. 2013;39:365–78.
14. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007;8:21–34.
15. Cui H, López M, Rahmouni K. The cellular and molecular bases of leptin and ghrelin resistance in obesity. Nat Rev Endocrinol. 2017;13:338–51.
16. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered. 1950;41:317–8.
17. Zibadi S, Cordova F, Slack EH, Watson RR, Lanson DF. Leptin’s regulation of obesity-induced cardiac extracellular matrix remodeling. Cardiovasc Toxicol. 2011;11:325–33.
18. Huang K, Rabold R, Abston E, Schofield B, Misra V, Galdzicka E, Lee H, Biswal S, Mitzner W, Tankersley CG. Effects of leptin deficiency on postnatal lung development in mice. J Appl Physiol. 2008;105:249–59.
19. Jain M, Budinger GRS, Lo A, et al. Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-y. Am J Respir Crit Care Med. 2011;183:1490–8.
20. Müller TD, Sullivan LM, Habegger K, et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci. 2012;18:383–93.
21. Chen M, Hegde A, Choi YH, Thenot BS, Premont RT, Chen W, Walker JL. Genetic deletion of β- arrestin-2 and the mitigation of established airway hyperresponsiveness in a murine asthma model. Am J Respir Cell Mol Biol. 2015;53:346–54.
22. Ingram JL, Huggins MJ, Church TD, et al. Airway fibroblasts in asthma manifest an invasive phenotype. Am J Respir Crit Care Med. 2011;183:1625–32.
23. Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression—a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinform. 2006;7:123.
24. Kurokawa A, Kondo M, Airmura K, Ashino S, Tagaya E. Less airway inflammation and goblet cell metaplasia in an IL-33-induced asthma model of leptin-deficient obese mice. Respir Res. 2021;22:166.
25. Shore SA, Schwartzman IN, Melvema MS, Flynn LT, Innoch A, Johnston RA. Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol. 2005;115:103–9.
26. Vernooy JH, Bracke KR, Drummen NEA, Pauwels NSA, Zabeau L, van Suylen RJ, Tavernier J, Joois GF, Wouters EFM, Brusselle GG. Leptin modulates innate and adaptive immune cell recruitment after cigarette smoke exposure in mice. J Immunol. 2010;184:7169–77.
27. Landgraf MA, Silva RC, Corrêa-Costa M, Hiyane MI, Carvalho MHC, Landgraf RG, Cámera NOS. Leptin downregulates LPS-induced lung injury: role of corticosterone and insulin. Cell Physiol Biochem. 2014;33:835–46.
28. Dong HY, Xu M, JI ZY, et al. Leptin attenuates lipopolysaccharide or oleic acid-induced acute lung injury in mice. Am J Respir Cell Mol Biol. 2013;49:1057–63.
29. Mancuso P, Huffnagle GB, Olszewski MA, Phipps J, Peters-Golden M. Leptin corrects host defense defects after acute starvation in murine pneumococcal pneumonia. Am J Respir Crit Care Med. 2006;173:212–8.
30. Hao W, Wang J, Zhang Y, Wang Y, Sun L, Han W. Leptin positively regulates MUC5AC production and secretion induced by interleukin-13 in human bronchial epithelial cells. Biochem Biophys Res Commun. 2017;493:797–84.
31. Fuseini H, Newcomb DC. Mechanisms driving gender differences in asthma. Curr Allergy Asthma Rep. 2017;17:19.
32. Christen T, Trompet S, Noordam R, et al. Sex differences in body fat distribution are related to sex differences in serum leptin and adiponectin. Peptides. 2018;107:25–31.
33. Hellstrom I, Wahrenberg H, Hruska K, Reinsdottir S, Arner P. Mechanisms behind gender differences in circulating leptin levels. J Intern Med. 2000;247:547–62.
34. Asarian L, Geary N. Sex differences in the physiology of eating. Am J Physiol Regul Integr Comp Physiol. 2013;305:R1215–67.
35. Chang HYS, Mitzner W. Sex differences in mouse models of asthma. Can J Physiol Pharmacol. 2007;85:1226–35.
36. Card JW, Carey MA, Bradbury JA, DeGraff LM, Morgan DL, Moorman MP, Flack GP, Zeldin DC. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol. 2006;177:621–30.
37. Berger S, Pho H, Fleury-Curado T, et al. Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity. Am J Respir Crit Care Med. 2019;199:773–83.
38. Freire C, Pho H, Kim LJ, Wang X, Dyavanapalli J, Streeter SR, Fleury-Curado T, Sennes LU, Mendelowitz D, Polotsky VY. Intranasal leptin prevents opioid-induced sleep-disordered breathing in obese mice. Am J Respir Cell Mol Biol. 2020;63:502–9.
39. Do J, Chang Z, Sekerková G, McCrimmon DR, Martina M. A leptin-mediated neural mechanism linking breathing to metabolism. Cell Rep. 2020;33:108358.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.